BTI
ADCT icon

Blue Trust Inc’s ADC Therapeutics ADCT Stock Holding History

Blue Trust Inc’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-31
Closed – – 2270
2022
Q4 		$0 Buy
+31
New +$124 ﹤0.01% 2194

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Blue Trust Inc's ADCT Position: Q1 2023 in Review

Blue Trust Inc sold out of ADC Therapeutics (ADCT) in Q1 2023, closing a stake of 31 shares.

Blue Trust Inc first reported a position in ADCT in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2023.

  • Blue Trust Inc reported no remaining ADC Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Blue Trust Inc sold 31 ADC Therapeutics shares in Q1 2023.
  • Blue Trust Inc first reported a position in ADC Therapeutics in Q4 2022 and held it in 1 quarter.
  • Blue Trust Inc's ADC Therapeutics position peaked at $0 in Q4 2022.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2023.

Based on Blue Trust Inc's 13F filing for Q1 2023, filed 17 Apr 2023.